Sept 11 (Reuters) - Abraxis BioScience Inc (ABBI.O: Quote, Profile, Research) said it received tentative approval from U.S. health regulators for its generic version of Roche’s (ROG.VX: Quote, Profile, Research) kytril injection that prevents nausea and vomiting caused by cancer chemotherapy.
